Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 2,513 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: RAPID Clear all

Conditions: Brain Concussion, Mild Cognitive Impairment
Interventions: Pen and paper neuropsychological test, Quick Test; Other · Device
Lead sponsor: ImPACT Applications, Inc.; Industry
Eligibility: 6 Years to 75 Years
Enrollment: 1,600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 4
States / cities: Scottsdale, Arizona • Fayetteville, Arkansas • Crofton, Maryland + 1 more

Conditions: Obesity, Healthy
Interventions: PET Scan, Mixed Meal Test, Muscle sympathetic nerve activity (MSNA), Oral Glucose Tolerance Test, Body Composition, Percent Body Fat & Percent Body Water (Tanita scale), CT Scan, Body Composition, Percent Body Fat & Percent Body Water (DXA Scan); Diagnostic Test · Dietary Supplement · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Scoliosis
Interventions: 3D topographical scan; Diagnostic Test
Lead sponsor: NSite Medical; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 2
States / cities: Palo Alto, California • Durham, North Carolina

Conditions: MRI Scans
Interventions: Adenosine, Regadenoson, O-15 labeled radioactive water, MRI, PET Imaging; Drug · Device
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Pulmonary Embolism, Deep Vein Thrombosis, Atrial Fibrillation
Interventions: Warfarin; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Agitation Associated With Alzheimer's Dementia
Interventions: ITI-1284, Placebo; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 32
States / cities: Anaheim, California • Costa Mesa, California • Garden Grove, California + 19 more

Conditions: Heart Disease
Interventions: BioNIR Ridaforolimus Eluting Coronary Stent; Device
Lead sponsor: Medinol Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 2
States / cities: Scottsdale, Arizona • Petoskey, Michigan

Conditions: Hypercholesterolemia, Hyperlipidemia, Vitamin Deficiency, Obesity
Interventions: Fortified eggs, Intermittent fasting, Non-egg supplemented, Usual care diet; Dietary Supplement · Behavioral
Lead sponsor: Duke University; Other
Eligibility: 50 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Migraine Disorders
Interventions: Placebo, Combination Product (sumatriptan succinate/naproxen sodium); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 28
States / cities: Jasper, Alabama • Oceanside, California • San Francisco, California + 25 more

Conditions: Healthy
Interventions: Colchicine, Seville Orange Juice; Drug · Other
Lead sponsor: Mutual Pharmaceutical Company, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Type 1 Diabetes
Interventions: AIDANET; Device
Lead sponsor: Marc Breton; Other
Eligibility: 18 Years to 60 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Diabetic Macular Edema
Interventions: Macugen (Pegaptanib Sodium); Drug
Lead sponsor: Retina Institute of Hawaii; Other
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Chest Pain
Interventions: Outpatient Evaluation, Hospitalization Evaluation; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years and older
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 3
States / cities: Detroit, Michigan • Charlotte, North Carolina • Winston-Salem, North Carolina

Conditions: Healthy Adults
Interventions: Crucera-SGS, Meriva 500-SF; Dietary Supplement
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Centanafadine; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 9 Years to 12 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Myeloid Leukemia, in Relapse, MDS
Interventions: MT-401-OTS; Drug
Lead sponsor: Marker Therapeutics, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Duarte, California • Tampa, Florida • Kansas City, Kansas

Conditions: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions: Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177); Biological · Other · Drug
Lead sponsor: Beat AML, LLC; Other
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2032
U.S. locations: 31
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more

Conditions: Hematopoietic Stem Cell Transplantation
Interventions: Melphalan; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Glomerular Filtration Rate
Interventions: Lumitrace, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR); Device
Lead sponsor: MediBeacon; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Type 1 Diabetes Mellitus
Interventions: Tandem t:slim X2 with Control-IQ Technology + Dexcom G6, Dexcom CGM G5, Continuous Subcutaneous Insulin Infusion; Device
Lead sponsor: University of Virginia; Other
Eligibility: 6 Years to 18 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Stanford, California • Aurora, Colorado • Charlottesville, Virginia

Conditions: Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Moderate Chronic Obstructive Pulmonary Disease, Asthma
Interventions: Technosphere® Insulin, Usual Care; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 12
States / cities: Mission Hills, California • San Diego, California • Palm Harbor, Florida + 8 more

Conditions: Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
Interventions: Hyperpolarized 13C-Pyruvate, Computed tomography (CT), Magnetic Resonance Imaging (MRI); Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hepatic Failure, Hepatic Impairment, Chronic Hepatitis C Infection With Hepatic Coma
Interventions: 2.0mg Buprenorphine/0.5mg Naloxone, Promethazine; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Hialeah, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, Metformin, DA-1241; Drug
Lead sponsor: Dong-A ST Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Development of a Neurocognitive Screening Test

Sympathetic Activation in Obesity

Study of 3D Scanning for Adolescent Scoliosis

Comparison of Quantitative MRI Perfusion Methods With Quantitative PET Perfusion Imaging

Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information

A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia

BIONICS - Pharmacokinetics (PK) Trial

PROSPective Evaluation of Fortified Eggs Related to Improvement in The Biomarker Profile for Your Health

A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)

Drug-Food Interaction Study of Seville Orange Juice and Colchicine

Safety and Feasibility Testing of a Smaller Network Version of AIDANET

A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema

CARE-CP (Testing a Cardiovascular Ambulatory Rapid Evaluation for Patients With Chest Pain)

Effect of Orally Delivered Phytochemicals on Aging and Inflammation in the Skin

Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)

Safety of MT-401-OTS in Patients With Relapsed AML or MDS

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

A Pharmacokinetic Study of Melphalan in Children

Evaluation of Protein Loading on Measurement of Renal Reserve

Artificial Pancreas and Remote Monitoring During a T1DM Youth Ski Camp

Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease

Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer

Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects

A Study To Evaluate The Safety,Tolerability, PK and PD Of DA-1241 In Healthy Male Subjects